These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18545772)

  • 41. Dopamine Replacement Medication Does Not Influence Implicit Learning of a Stepping Task in People With Parkinson's Disease.
    Paul SS; Schaefer SY; Olivier GN; Walter CS; Lohse KR; Dibble LE
    Neurorehabil Neural Repair; 2018 Dec; 32(12):1031-1042. PubMed ID: 30409107
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET.
    Cools R; Stefanova E; Barker RA; Robbins TW; Owen AM
    Brain; 2002 Mar; 125(Pt 3):584-94. PubMed ID: 11872615
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The concept of continuous dopaminergic stimulation in the treatment of late stages of Parkinson's disease].
    Titova NV; Katunina EA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(12):105-12. PubMed ID: 24596973
    [No Abstract]   [Full Text] [Related]  

  • 44. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Loss of phosphodiesterase 4 in Parkinson disease: Relevance to cognitive deficits.
    Niccolini F; Wilson H; Pagano G; Coello C; Mehta MA; Searle GE; Gunn RN; Rabiner EA; Foltynie T; Politis M
    Neurology; 2017 Aug; 89(6):586-593. PubMed ID: 28701494
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluating the acute contributions of dopaminergic replacement to gait with obstacles in Parkinson's disease.
    Pieruccini-Faria F; Vitório R; Almeida QJ; Silveira CR; Caetano MJ; Stella F; Gobbi S; Gobbi LT
    J Mot Behav; 2013; 45(5):369-80. PubMed ID: 23834709
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Motor fluctuations in levodopa treatment: clinical pharmacology.
    Stocchi F; Bonamartini A; Vacca L; Ruggieri S
    Eur Neurol; 1996; 36 Suppl 1():38-42. PubMed ID: 8791020
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems.
    Carlsson A
    J Neural Transm (Vienna); 2002 May; 109(5-6):777-87. PubMed ID: 12111467
    [No Abstract]   [Full Text] [Related]  

  • 49. [Optimization of the treatment of Parkinson's disease using dopamine agonists].
    Rinne UK
    Arch Neurobiol (Madr); 1991; 54(6):282-7. PubMed ID: 1687430
    [No Abstract]   [Full Text] [Related]  

  • 50. Visuomotor adaptation in Parkinson's disease: effects of perturbation type and medication state.
    Semrau JA; Perlmutter JS; Thoroughman KA
    J Neurophysiol; 2014 Jun; 111(12):2675-87. PubMed ID: 24694937
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Age at Parkinson's disease onset modulates the effect of levodopa on response inhibition: Support for the dopamine overdose hypothesis from the antisaccade task.
    Waldthaler J; Stock L; Krüger-Zechlin C; Timmermann L
    Neuropsychologia; 2021 Dec; 163():108082. PubMed ID: 34728241
    [TBL] [Abstract][Full Text] [Related]  

  • 52. On the role of dopamine replacement therapy in decision-making, working memory, and reward in Parkinson's disease: does the therapy-dose matter?
    Torta DM; Castelli L; Zibetti M; Lopiano L; Geminiani G
    Brain Cogn; 2009 Nov; 71(2):84-91. PubMed ID: 19442427
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Parkinson's disease].
    Yokochi M
    Ryoikibetsu Shokogun Shirizu; 1999; (27 Pt 2):5-14. PubMed ID: 10434578
    [No Abstract]   [Full Text] [Related]  

  • 54. A dopamine agonist, pramipexole, and cognitive functions in Parkinson's disease.
    Relja M; Klepac N
    J Neurol Sci; 2006 Oct; 248(1-2):251-4. PubMed ID: 16797593
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Folate and vitamin B12 levels in levodopa-treated Parkinson's disease patients: their relationship to clinical manifestations, mood and cognition.
    Triantafyllou NI; Nikolaou C; Boufidou F; Angelopoulos E; Rentzos M; Kararizou E; Evangelopoulos ME; Vassilopoulos D
    Parkinsonism Relat Disord; 2008; 14(4):321-5. PubMed ID: 18055246
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of L-DOPA on spatiotemporal contrast sensitivity in Parkinson's disease.
    Mestre DR; Blin O; van den Brand CL; Azulay JP; Serratrice G
    Adv Neurol; 1996; 69():503-11. PubMed ID: 8615172
    [No Abstract]   [Full Text] [Related]  

  • 57. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease.
    Fera F; Nicoletti G; Cerasa A; Romeo N; Gallo O; Gioia MC; Arabia G; Pugliese P; Zappia M; Quattrone A
    Brain Res Bull; 2007 Sep; 74(1-3):75-83. PubMed ID: 17683792
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dysfunctional inhibitory control in Parkinson's disease patients with levodopa-induced dyskinesias.
    Picazio S; Ponzo V; Caltagirone C; Brusa L; Koch G
    J Neurol; 2018 Sep; 265(9):2088-2096. PubMed ID: 29980853
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recognition of category-related visual stimuli in Parkinson's disease: before and after pharmacological treatment.
    Righi S; Viggiano MP; Paganini M; Ramat S; Marini P
    Neuropsychologia; 2007 Oct; 45(13):2931-41. PubMed ID: 17662314
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias.
    Bachmann CG; Zapf A; Brunner E; Trenkwalder C
    Eur J Neurol; 2009 Aug; 16(8):895-901. PubMed ID: 19374662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.